Original Articles Open access

Anticholinergic and sedative medication burden in older adults: an observational analysis

Authors

Published
6 November 2025
Section
Original Articles
DOI
10.4081/gc.2025.14173

Abstract

The cumulative effects of multiple medications with anticholinergic and sedative properties, referred to as anticholinergic and sedative burdens, can result in adverse effects in older adults. This study aimed to evaluate the exposure of older adult patients to anticholinergic and sedative medications. This cross-sectional study included older adult patients (aged ≥60 years) admitted to the geriatric inpatient wards. The anticholinergic burden was assessed using the CRIDECO scale, and the Drug Burden Index (DBI) quantified the cumulative anticholinergic and sedative burden. The data obtained were categorically assessed and are represented as [n (%)]. The associations between medication burden and health outcomes were analyzed using appropriate tests. The mean age of the participants in the study cohort was 72.80±7.41 years. Among the participants, 29.17% were administered at least one anticholinergic medication, with a mean cumulative Anticholinergic Cognitive Burden (ACB) score of 2.49±2.00. The majority (94.34%) had a cumulative DBI score of ≥1, with a mean DBI score of 3.14±1.55. Linear regression analysis demonstrated that both ACB and DBI were significant predictors of the length of hospitalization (ACB: p=0.002; DBI: p=0.001), whereas only DBI was associated with the Charlson Comorbidity Index (p=0.001). Logistic regression revealed that ACB scores significantly predicted cognitive decline (p=0.047). This study highlights the high prevalence of anticholinergic and sedative medication use among hospitalized older adult patients and its association with adverse health outcomes. Regular medication reviews and targeted deprescribing strategies are essential to reduce the medication burden in this vulnerable population.

Keywords

References

  1. World Health Organization. Ageing and health. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
  2. Kouladjian L, Gnjidic D, Chen TF, et al. Drug burden index in older adults: theoretical and practical issues. Clin Interv Aging 2014;9:1503-15. DOI: https://doi.org/10.2147/CIA.S66660
  3. Arthur A, Savva GM, Barnes LE, et al. Changing prevalence and treatment of depression among older people over two decades. Br J Psychiatry 2020;216:49-54. DOI: https://doi.org/10.1192/bjp.2019.193
  4. Lim R, Kalisch Ellett LM, Widagdo IS, et al. Analysis of anticholinergic and sedative medicine effects on physical function, cognitive function, appetite and frailty: a cross-sectional study in Australia. BMJ Open 2019;9:e029221. DOI: https://doi.org/10.1136/bmjopen-2019-029221
  5. Bishara D. Anticholinergic action is rarely a good thing. Ther Adv Psychopharmacol 2023;13:20451253231195264. DOI: https://doi.org/10.1177/20451253231195264
  6. Ghossein N, Kang M, Lakhkar AD. Anticholinergic medications. Treasure Island, FL, USA: StatPearls Publishing; 2025.
  7. Reallon E, Gervais F, Moutet C, et al. Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study Alzheimers Res Ther 2024;16:163. Erratum in: Alzheimers Res Ther 2024;16:195. DOI: https://doi.org/10.1186/s13195-024-01530-8
  8. Ramos H, Moreno L, Pérez-Tur J, et al. CRIDECO anticholinergic load scale: an updated anticholinergic burden scale. Comparison with the ACB scale in Spanish individuals with subjective memory complaints. J Pers Med 2022;12:207. DOI: https://doi.org/10.3390/jpm12020207
  9. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007;167:781-7. DOI: https://doi.org/10.1001/archinte.167.8.781
  10. Jyani G, Sharma A, Prinja S, et al. Development of an EQ-5D value set for India using an extended design (DEVINE) study: the Indian 5-level version EQ-5D value set. Value Health 2022;25:1218-26. DOI: https://doi.org/10.1016/j.jval.2021.11.1370
  11. Abellan van Kan G, Rolland YM, Morley JE, Vellas B. Frailty: toward a clinical definition. J Am Med Dir Assoc 2008;9:71-2. DOI: https://doi.org/10.1016/j.jamda.2007.11.005
  12. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14:531-2. DOI: https://doi.org/10.1016/j.jamda.2013.05.018
  13. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003;51:1451-4. DOI: https://doi.org/10.1046/j.1532-5415.2003.51465.x
  14. Cross AJ, George J, Woodward MC, et al. Potentially inappropriate medications and anticholinergic burden in older people attending memory clinics in Australia. Drugs Aging 2016;33:37-44. DOI: https://doi.org/10.1007/s40266-015-0332-3
  15. Weichert I, Romero-Ortuno R, Tolonen J, et al. Anticholinergic medications in patients admitted with cognitive impairment or falls (AMiCI). The impact of hospital admission on anticholinergic cognitive medication burden. Results of a multicentre observational study. J Clin Pharm Ther 2018;43:682-94. DOI: https://doi.org/10.1111/jcpt.12694
  16. Mantri S, Fullard M, Gray SL, et al. Patterns of dementia treatment and frank prescribing errors in older adults with parkinson disease. JAMA Neurol 2019;76:41-9. DOI: https://doi.org/10.1001/jamaneurol.2018.2820
  17. Lampela P, Taipale H, Lavikainen P, Hartikainen S. The effect of comprehensive geriatric assessment on anticholinergic exposure assessed by four ranked anticholinergic lists. Arch Gerontol Geriatr 2017;68:195-201. DOI: https://doi.org/10.1016/j.archger.2016.10.014
  18. Raei K, Rahimi A, Hosseini SR, et al. Anticholinergic drug use in elderly people: a population- based study in Iran. Caspian J Intern Med 2021;12:593-9.
  19. Grossi CM, Richardson K, Savva GM, et al. Increasing prevalence of anticholinergic medication use in older people in England over 20 years: cognitive function and ageing study I and II. BMC Geriatr 2020;20:267. DOI: https://doi.org/10.1186/s12877-020-01657-x
  20. Shmuel S, Pate V, Pepin MJ, et al. Quantifying cumulative anticholinergic and sedative drug load among US medicare beneficiaries. Pharmacoepidemiol Drug Saf 2021;30:144-56. DOI: https://doi.org/10.1002/pds.5144
  21. Lowry E, Woodman RJ, Soiza RL, et al. Drug burden index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol 2012;52:1584-91. DOI: https://doi.org/10.1177/0091270011421489
  22. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 2015;15:31. DOI: https://doi.org/10.1186/s12877-015-0029-9
  23. Bosboom PR, Alfonso H, Eaton J, Almeida OP. Quality of life in Alzheimer’s disease: different factors associated with complementary ratings by patients and family carers. Int Psychogeriatr 2012;24:708-21. DOI: https://doi.org/10.1017/S1041610211002493
  24. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175:401-7. DOI: https://doi.org/10.1001/jamainternmed.2014.7663
  25. Byrne CJ, Walsh C, Cahir C, Bennett K. Impact of drug burden index on adverse health outcomes in Irish community-dwelling older people: a cohort study. BMC Geriatr 2019;19:121. DOI: https://doi.org/10.1186/s12877-019-1138-7
  26. Chatterjee K, Dangi A, Sharma R, et al. Adding pre-emptive anticholinergics to antipsychotics: Is it justified? Ind Psychiatry J 2022;31:370-3. DOI: https://doi.org/10.4103/ipj.ipj_269_21
  27. World Health Organization. Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders. Available from: https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre/psychosis-and-bipolar-disorders/role-of-anticholinergic-medications-in-patients-requiring-long-term-antipsychotic-treatment-for-psychotic-disorders.
  28. Gallucci M, Pallucca C, Di Battista ME, et al. Anti-cholinergic derangement of cortical metabolism on 18F-FDG PET in a patient with frontotemporal lobar degeneration dementia: a case of the TREDEM registry. J Alzheimers Dis 2020;74:1107-17. DOI: https://doi.org/10.3233/JAD-191290

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.